Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate

REFERENCES

• Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185–6.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–88.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
   PubMed Web of Science ®Google Scholar
• Criscione LG, St Clair EW. Tumor necrosis factor-alpha antag-onists for the treatment of rheumatic diseases. Curr Opin Rheu-matol. 2002;14:204–11.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy Study Group. N Engl J Med. 2000;343:1594–602.
   Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleisch-mann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumornecrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum. 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349: 1907–15.
   Google Scholar
• Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford). 2008;47:1461–8.
   PubMed Web of Science ®Google Scholar
• Sugita M, Kumagai S, Ota M, Inoko H, Tsuji K, Imura H. Demonstration of the requirement for self antigen in the activa-tion of autoreactive T cells. Int Immunol. 1992;4:119–24.
   PubMedGoogle Scholar
• Moreland LW, Alten R, Van den BF, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheu-matoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthr Rheum. 2002;46:1470–9.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353 :1114–23.
   PubMed Web of Science ®Google Scholar
• Amano K, Abe T, Takeuchi T, Yamamoto A, Miyasaka N. A phase I study to evaluate the safety, tolerability and efficacy of abatacept in Japanese rheumatoid arthritis patients (abstract). International Journal of Rheumatic Diseases 2010; 14th Congress of Asia Pacific League of Associations for Rheumatology, 12–2.4-0364.
   Google Scholar
• Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheuma-toid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096–103.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costi-mulation modulator abatacept: twelve-month results of a phase II13, double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2005;52:2263–71.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza MC, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
   Google Scholar
• Westhovens R, Robles M, Ximenes AC, Nayiager S, Wol-lenhaupt J, Durez P, et al. Clinical efficacy and safety of abata-cept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–7.
   Google Scholar
• Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multi-centre randomized clinical trial. Rheumatology (Oxford). 2006;45 :1238–46.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving backgroundbiologic and nonbiologic disease-modifying antirheumatic drugs. Arthr Rheum. 2011;54:2807–16.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthr Rheum. 1992;35:498–502.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Pre-liminary definition of improvement in rheumatoid arthritis. Arthr Rheum. 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum. 1998;41:1564–70.
   Google Scholar
• Haggerty HG, Abbott MA, Reilly TP, DeVona DA, Gleason CR, Tay L, et al. Evaluation of immunogenicity of the T cell costi-mulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34:2365–73.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28–32.
   PubMedGoogle Scholar
• Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DA528) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DA528 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954–60.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, etal. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr Rheum. 2004;50: 1761–9.
   Google Scholar
• Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252–62.
   PubMed Web of Science ®Google Scholar
• Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichi-kawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose metho-trexate in Japanese patients with rheumatoid arthritis. J Rheuma-tol. 2006;33:37–44.
   Google Scholar
• Phase II dose-finding clinical trials for etanercept. Enbrel [online] 2010. http://www.enbrel.jp/member/datairesult.html.
   Google Scholar
• Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y, et al. The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet. 2011;20:2680–5.
   PubMed Web of Science ®Google Scholar
• Kochi Y, Suzuki A, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid arthritis-implications for patho-genesis. Nat Rev Rheumatol. 2010;6:290–5.
   PubMed Web of Science ®Google Scholar